Literature DB >> 6243650

Binding of cholecystokinin to high affinity receptors on isolated rat pancreatic acini.

H Sankaran, I D Goldfine, C W Deveney, K Y Wong, J A Williams.   

Abstract

The binding of cholecystokinin (CCK) to its receptors on isolated rat pancreatic acini was investigated employing high specific activity, radioiodinated CCK (125I-BH-CCK), prepared by the conjugation of 125I-Bolton-Hunter reagent (125I-BH) to CCK. Binding was specific, time-dependent, reversible, and linearly related to the acinar protein concentration. After incubation for 30 min at 37 degrees C, the 125I-BH-CCK both in the incubation medium and bound to acini remained intact, as judged by gel filtration and trichloroacetic acid precipitation studies. Scatchard analysis was compatible with two classes of binding sites on acini: a very high affinity site (Kd, 64 pM) and a lower affinity site (Kd, 21 nM). 125I-BH-CCK binding to acini was competitively inhibited by CCK and four of its analogues in proportion to their biological potencies but not by unrelated hormones. Stimulation of amylase secretion by CCK and inhibition of 125I-BH-CCK binding by the same analogues carried out under identical conditions revealed a correlation (r = 0.99) between binding potency and amylase secretion. Stimulation of amylase secretion by CCK closely paralleled the occupancy of the high affinity CCK binding sites. It is concluded that the high affinity CCK binding sites most likely are the receptors mediating the stimulation of amylase secretion by CCK.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6243650

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  Pharmacological comparison of the alternatively spliced short and long CCK2 receptors.

Authors:  M F Morton; E A Harper; I A Tavares; N P Shankley
Journal:  Br J Pharmacol       Date:  2003-08-04       Impact factor: 8.739

2.  Pharmacological evidence for putative CCK(1) receptor heterogeneity in human colon smooth muscle.

Authors:  M F Morton; E A Harper; I A Tavares; N P Shankley
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

3.  Molecular cloning, expression and pharmacological characterization of the canine cholecystokinin 1 receptor.

Authors:  Magda Francesca Morton; Jayashree Pyati; Heng Dai; Lina Li; Veronica Moreno; Nigel Paul Shankley
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

4.  Expression and Regulation of Cholecystokinin Receptor in the Chicken's Immune Organs and Cells.

Authors:  Seham El-Kassas; Solomon Odemuyiwa; George Hajishengallis; Terry D Connell; Toufic O Nashar
Journal:  J Clin Cell Immunol       Date:  2016-11-25

5.  Contributing mechanisms underlying desensitization of cholecystokinin-induced activation of primary nodose ganglia neurons.

Authors:  Cody W Kowalski; Jonathan E M Lindberg; Daniel K Fowler; Steven M Simasko; James H Peters
Journal:  Am J Physiol Cell Physiol       Date:  2020-02-19       Impact factor: 4.249

6.  The effect of gastrointestinal hormones on the incorporation of tritiated thymidine in the pancreatic adenocarcinoma cell line (WD PaCa).

Authors:  B F Edwards; T W Redding; A V Schally
Journal:  Int J Pancreatol       Date:  1989-09

7.  Modulation of cholecystokinin activity by albumin.

Authors:  S C Huang; V D Talkad; K P Fortune; S Jonnalagadda; C Severi; G Delle Fave; J D Gardner
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

8.  Exogenous administration of estradiol and cholecystokinin alters exocrine pancreatic function in rats.

Authors:  A Tangoku; R Doi; P Chowdhury; G T Blevins; J N Pasley; P L Rayford
Journal:  Int J Pancreatol       Date:  1993-04

9.  Cytosolic calcium regulates epidermal growth factor endocytosis in rat pancreas and cultured fibroblasts.

Authors:  M Korc; L M Matrisian; B E Magun
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

10.  Gastrin receptors on isolated canine parietal cells.

Authors:  A H Soll; D A Amirian; L P Thomas; T J Reedy; J D Elashoff
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.